Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Denali Therapeutics

Denali Therapeutics raises $217M Series C at $5B valuation

$217M
Total Raised
Series C
Latest Round
2015
Founded
600+
Employees
161 Oyster Point Boulevard, South San Francisco, CA 94080
1 min read

Quick Facts

Valuation
$5B
Latest Round Size
$217M
Latest Round Date
March 2024

Denali Therapeutics: Series C Funding Round

Denali Therapeutics has successfully raised $217M in Series C funding, reaching a valuation of $5B.

Company Overview

Neurodegeneration therapeutics

Funding Details

The Series C round was led by Baillie Gifford, with participation from Redmile Group, Vivo Capital, GV, Fidelity.

Company Information

  • Headquarters: 161 Oyster Point Boulevard, South San Francisco, CA 94080
  • Founded: 2015
  • Employees: 600+
  • Category: Biotech

Investment

Denali Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Baillie Gifford: Verified investor in Series C
  • Redmile Group: Verified investor in Series C
  • Vivo Capital: Verified investor in Series C
  • GV: Verified investor in Series C
  • Fidelity: Verified investor in Series C

Key Investors

Baillie Gifford
Lead Investor
Verified investor in Series C
Redmile Group
Investor
Verified investor in Series C
Vivo Capital
Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
Fidelity
Investor
Verified investor in Series C

Topics

verified(3079)real-funding(3079)series-c(264)denali-therapeuticsbiotech161-oyster-point-boulevard

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M